Bassiatin which is produced by some fungi, is
morpholine-based
depsipeptide. Recent studies show that
bassiatin inhibits MCF-7
breast cancer cell proliferation with its anti-oestrogenic effect. In this study,
bassiatin's inhibition versus
Tamoxifen was examined by comparing the effects on
epidermal growth factor receptor and
vascular endothelial growth factor receptor in addition to oestrogen receptor on breast cells. For this purpose, 15 concentrations of
bassiatin,
tamoxifen and combination of both were treated in terms of cytotoxicity on MCF-7, MDA-MB-231, SK-BR-3 and SVCT cell lines. For cell cycle analyses, MCF-7 and SVCT cell lines were incubated with 37.5 μM
bassiatin,
tamoxifen and combined substance for 24 h and 48 h.
After treatment, cell distribution in each phase of the cell cycle was measured with flow cytometer. Furthermore, each interaction related to receptors were investigated with immunoassay ELISA kits. As a result,
bassiatin-induced MCF-7 cell cycle arrest was shown in G0/G1 and G2/M phases at the presence of
bassiatin. It was also found that
bassiatin is more effective at all examined receptors on
breast cancer cells than
tamoxifen. These results show that
bassiatin can be used effectively in
breast cancer treatment as a new
anticancer agent because of its multiple inhibition effects.